Published in Brain on January 19, 2005
Parkinson's disease: gene therapies. Cold Spring Harb Perspect Med (2012) 1.13
Available and emerging treatments for Parkinson's disease: a review. Drug Des Devel Ther (2011) 0.87
The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study. PLoS One (2011) 0.85
Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Sci Rep (2013) 0.81
Potential cellular and regenerative approaches for the treatment of Parkinson's disease. Neuropsychiatr Dis Treat (2008) 0.79
Human amniotic epithelial cells express specific markers of nerve cells and migrate along the nerve fibers in the corpus callosum. Neural Regen Res (2012) 0.76
The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats. PLoS One (2012) 0.76
Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease. Mol Ther (2015) 0.75
Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med (2002) 10.10
Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol (2006) 7.32
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods (2002) 5.30
Direct conversion of human fibroblasts to dopaminergic neurons. Proc Natl Acad Sci U S A (2011) 4.81
Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A (2008) 3.84
TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc Natl Acad Sci U S A (2013) 3.33
Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci (2002) 3.12
Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol (2003) 2.93
Generation of induced neurons via direct conversion in vivo. Proc Natl Acad Sci U S A (2013) 2.51
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain (2007) 2.49
Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther (2005) 2.47
Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78. Proc Natl Acad Sci U S A (2010) 2.40
A general chemical method to regulate protein stability in the mammalian central nervous system. Chem Biol (2010) 2.39
Myeloid and lymphoid contribution to non-haematopoietic lineages through irradiation-induced heterotypic cell fusion. Nat Cell Biol (2008) 2.17
Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol (2007) 2.15
Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol (2004) 2.12
Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain (2005) 2.06
The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A (2008) 2.00
Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J Virol (2006) 1.97
Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology (2008) 1.96
An ORC/Cdc6/MCM2-7 complex is formed in a multistep reaction to serve as a platform for MCM double-hexamer assembly. Mol Cell (2013) 1.94
Cell therapy in Parkinson's disease. NeuroRx (2004) 1.93
Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 1.92
Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J Neurosci (2009) 1.89
Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther (2006) 1.83
Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2. J Virol (2002) 1.77
Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci (2002) 1.74
Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp Neurol (2003) 1.72
Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol (2013) 1.72
Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol (2004) 1.67
Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther (2007) 1.67
Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J Neurosci (2005) 1.67
[¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology (2012) 1.64
Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci (2004) 1.61
Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells. Proc Natl Acad Sci U S A (2009) 1.57
Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther (2007) 1.55
Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther (2006) 1.54
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis (2002) 1.54
Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther (2009) 1.52
Cell transplantation in Parkinson's disease: how can we make it work? Trends Neurosci (2005) 1.51
Myosin IIb regulates actin dynamics during synaptic plasticity and memory formation. Neuron (2010) 1.49
Structure of adeno-associated virus type 4. J Virol (2005) 1.47
Reduced juvenile long-term depression in tuberous sclerosis complex is mitigated in adults by compensatory recruitment of mGluR5 and Erk signaling. PLoS Biol (2013) 1.47
Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord (2010) 1.47
Recombinant adeno-associated viral vectors in the nervous system. Hum Gene Ther (2005) 1.46
Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain (2007) 1.45
Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J Struct Biol (2008) 1.44
Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Mov Disord (2013) 1.44
Neonatal intraperitoneal or intravenous injections of recombinant adeno-associated virus type 8 transduce dorsal root ganglia and lower motor neurons. Hum Gene Ther (2008) 1.42
Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci (2007) 1.42
α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med (2012) 1.40
Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A (2012) 1.40
GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease. Brain (2011) 1.38
Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus. Anticancer Res (2003) 1.35
Cell therapeutics in Parkinson's disease. Neurotherapeutics (2011) 1.32
Migration patterns and phenotypic differentiation of long-term expanded human neural progenitor cells after transplantation into the adult rat brain. Brain Res Dev Brain Res (2002) 1.32
Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol Ther (2005) 1.30
AAV9: a potential blood-brain barrier buster. Mol Ther (2009) 1.30
Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One (2010) 1.29
Feasibility of in vivo 15N MRS detection of hyperpolarized 15N labeled choline in rats. Phys Chem Chem Phys (2010) 1.28
Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. Hum Gene Ther (2004) 1.27
In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol Ther (2010) 1.26
Metabolic regulation of neuronal plasticity by the energy sensor AMPK. PLoS One (2010) 1.25